Pertuzumab biosimilar (NeuClone)

帕妥珠单抗生物类似药 (NeuClone)

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePertuzumab biosimilar (NeuClone)
Drug Alias Name帕妥珠单抗生物仿制药 (NeuClone)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNeuclone
China Registration ClassN/A

Develop Information

Active CompaniesNeucloneSerum Institute Of India Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC13
Related LinksN/A